See the DrugPatentWatch profile for lurbinectedin

Based on the information available, Lurbinectedin is an antineoplastic agent, which means it is used to treat cancer. However, there is limited information available regarding the fetal risks associated with this drug.

Pregnancy categories are used to classify the potential risks to a fetus when a medication is taken during pregnancy. According to the information provided by DrugPatentWatch.com, Lurbinectedin has not been assigned a pregnancy category by the FDA [1]. This could be due to a lack of sufficient data to determine the potential risks.

It is important to note that animal reproduction studies have not been conducted with Lurbinectedin, and it is not known whether Lurbinectedin can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity [2]. Therefore, Lurbinectedin should be given to a pregnant woman only if clearly needed.

In general, cancer treatments such as chemotherapy are known to pose potential risks to the fetus, including increased risk of miscarriage, stillbirth, and birth defects [3]. However, the specific risks associated with Lurbinectedin are not well-established due to limited data.

In summary, based on the available information, the fetal risks associated with Lurbinectedin are not well-established. However, due to the potential risks of cancer treatments in general, Lurbinectedin should only be used during pregnancy if clearly needed.

Sources:

1. DrugPatentWatch.com. Lurbinectedin. <https://www.drugpatentwatch.com/drugs/lurbinectedin>.
2. Zepzelca (lurbinectedin) [prescribing information]. Jazz Pharmaceuticals, Inc.; 2020. <https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214467s000lbl.pdf>.
3. American Cancer Society. Chemotherapy and pregnancy. <https://www.cancer.org/treatment/treatments-and-side-effects/physical-side-effects/fertility-and-sexual-side-effects/chemotherapy-and-pregnancy.html>.